These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36833429)

  • 1. Unexpected Findings in Hereditary Breast and Ovarian Cancer Syndrome: Low-Level Constitutional Mosaicism in
    Hidalgo Mayoral I; Almeida Santiago A; Sánchez-Zapardiel JM; Hidalgo Calero B; de la Hoya M; Gómez-Sanz A; de Miguel Reyes M; Robles L
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
    Alhopuro P; Vainionpää R; Anttonen AK; Aittomäki K; Nevanlinna H; Pöyhönen M
    Fam Cancer; 2020 Oct; 19(4):307-310. PubMed ID: 32468491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil.
    Cipriano NM; de Brito AM; de Oliveira ES; de Faria FC; Lemos S; Rodrigues AN; de Oliveira Lopes D; Dos Santos LL
    Breast Cancer; 2019 May; 26(3):397-405. PubMed ID: 30535581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
    Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
    Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.
    Santonocito C; Scapaticci M; Guarino D; Bartolini A; Minucci A; Concolino P; Scambia G; Paris I; Capoluongo E
    Breast; 2017 Dec; 36():74-78. PubMed ID: 29020660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
    Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
    Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
    PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
    Yoshida R
    Breast Cancer; 2021 Nov; 28(6):1167-1180. PubMed ID: 32862296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
    Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
    Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
    Cao WM; Zheng YB; Gao Y; Ding XW; Sun Y; Huang Y; Lou CJ; Pan ZW; Peng G; Wang XJ
    BMC Cancer; 2019 Jun; 19(1):551. PubMed ID: 31174498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.
    Montalban G; Bonache S; Bach V; Gisbert-Beamud A; Tenés A; Moles-Fernández A; López-Fernández A; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
    Cancer Genet; 2021 Nov; 258-259():10-17. PubMed ID: 34237702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays.
    Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Goina E; Acedo A; Buratti E; Velasco EA
    J Pathol; 2019 Aug; 248(4):409-420. PubMed ID: 30883759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.